Eloralintide (LY3841136) (10mg)

Eloralintide is a selective amylin receptor agonist. In in vitro data from the NCT05295940 publication, it preferentially activated the human AMY1R, with 12-fold selectivity over CTR and 11-fold selectivity over AMY3R. In preclinical data, it caused less conditioned taste avoidance in lean rats than cagrilintide. The Phase 1 pharmacokinetic profile supported the study of once-weekly dosing in subsequent trials.

• Laboratory reconstitution reference: 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
• Phase 2 NCT06230523: Arms of 1, 3, 6, and 9 mg once weekly, as well as 6–9 mg and 3–9 mg titration arms, for 48 weeks.
• Concentration mathematics: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 scale.
• Regulatory status: Investigational molecule; Phase 3 results from ENLIGHTEN have not been published.

1. In a reference laboratory calculation, 3.0 mL bacteriostatic water corresponds to a concentration of ~3.33 mg/mL for a 10 mg vial.
2. Gently add the diluent against the vial wall to limit foaming.
3. Continue to gently rotate until the lyophilized material is fully dissolved.
4. Storage conditions are determined by the investigational material's protocol and not by an approved product label.
5. Cloudiness or particulates are grounds for discarding the investigational solution.

• Molecule: Eloralintide (LY3841136), a selective amylin receptor agonist from Eli Lilly.
• Regulatory status: Under clinical development; not an approved drug.
• Phase 1 NCT05295940: A total of 148 participants. Includes a single ascending dose part of 0.04–12 mg in 48 healthy participants (mean BMI 27.5) and a separate 12-week multiple weekly dose part in 100 participants with obesity or who were overweight.
• Phase 2 NCT06230523: 263 participants, 48 weeks, 46 centers in the US.
• Phase 3 ENLIGHTEN: Five registered studies with unpublished results.
• Laboratory reference: 3.0 mL per hypothetical 10 mg vial (~3.33 mg/mL).

• Phase 1 NCT05295940: The publication reports single ascending doses of 0.04–12 mg.
• Phase 1 result: The 4 mg and 12 mg arms showed a mean change in body weight at week 4 of −2.5% and −4.4%, versus +0.6% with placebo.
• Phase 1 multiple dose (12 weeks): In a separate published part of weekly administration without titration, the mean change in body weight at week 12 ranged from −2.6% to −11.3% per arm, with minimal gastrointestinal adverse events (Diabetes Obes Metab 2026).
• Phase 2 NCT06230523: The publication reports weekly arms of 1, 3, 6, and 9 mg, as well as 6–9 mg and 3–9 mg titration.
• Phase 2 48-week result: −9% (1 mg), −12% (3 mg), −18% (6 mg), −20% (9 mg), −20% (6–9 mg), and −16% (3–9 mg), versus −0.4% with placebo.
• Interpretation: The above are published results of specific research arms and not usage instructions.
• Combination research: Registered studies are examining eloralintide in combination with macupatide (Phase 2/2b, NCT07589608 and NCT07215559) and with tirzepatide (Phase 2 NCT06603571, with preceding Phase 1 studies). There are no published results, and this does not constitute a recommendation for combination therapy.
• Break between cycles: A 2–4 week break is recommended before repeating the cycle.

• There is no approved product label with standardized storage conditions for eloralintide.
• Storage and stability conditions depend on the specific investigational material and the laboratory protocol.

• Eloralintide is an investigational molecule and is not approved by the FDA or EMA.
• Phase 1 and Phase 2 data have been published; the results of the Phase 3 ENLIGHTEN studies remain unpublished.
• The numerical values on this page exclusively represent the arms and results of the referenced trials.

1. The Lancet (2025) — Eloralintide Phase 2, NCT06230523 — 48 weeks, 263 participants
   View Source
2. Molecular Metabolism (2025) — Eloralintide Phase 1, NCT05295940 — from discovery to clinical proof-of-concept
   View Source
3. Diabetes Obes Metab (2026) — Eloralintide Phase 1 multiple dose, 12 weeks — proof-of-concept (−2.6% to −11.3%)
   View Source
4. Endocrinol Diabetes Metab (2026) — Network meta-analysis of amylin analogues — high-dose eloralintide ~−18% (indirect, preliminary)
   View Source
5. ClinicalTrials.gov — ENLIGHTEN-1 — NCT07321886
   View Source
6. ClinicalTrials.gov — ENLIGHTEN-2 — NCT07282600
   View Source
7. ClinicalTrials.gov — ENLIGHTEN-3 — NCT07392190
   View Source
8. ClinicalTrials.gov — ENLIGHTEN OSA — NCT07369011
   View Source
9. ClinicalTrials.gov — ENLIGHTEN knee osteoarthritis — NCT07353931
   View Source